Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Principal Investigator
Christina Tsien, MD
Status
Terminated
Date Opened To Accrual
December 20 2012
Date Closed to Accrual
April 28 2016
Date of Study Termination
December 22 2022
Disease Site
Brain [BN]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To establish an improvement in overall survival in recurrent GBM patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.
Patient Population
Patients with recurrent glioblastoma or variant (gliosarcoma or giant cell glioblastoma etc).
Target Accrual
178
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.